A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

Charles L. Bowden, Joseph R. Calabrese, Gary Sachs, Lakshmi N. Yatham, Shaheen Akthar Asghar, Magne Hompland, Paul Montgomery, Nancy Earl, Tonya M. Smoot, Joseph DeVeaugh-Geiss

Research output: Contribution to journalArticle

555 Citations (Scopus)

Abstract

Background: Lamotrigine has been shown to be an effective treatment for bipolar depression and rapid cycling in placebo-controlled clinical trials. This double-blind, placebo-controlled study was conducted to assess the efficacy and tolerability of lamotrigine and lithium compared with placebo for the prevention of relapse or recurrence of mood episodes in recently manic or hypomanic patients with bipolar I disorder. Methods: After an 8- to 16-week open-label phase during which treatment with lamotrigine was initiated and other psychotropic drug regimens were discontinued, patients were randomized to lamotrigine (100-400 mg daily), lithium (0.8-1.1 mEq/L), or placebo as double-blind maintenance treatment for as long as 18 months. Results: Of 349 patients who met screening criteria and entered the open-label phase, 175 met stabilization criteria and were randomized to double-blind maintenance treatment (lamotrigine, 59 patients; lithium, 46 patients; and placebo, 70 patients). Both lamotrigine and lithium were superior to placebo at prolonging the time to intervention for any mood episode (lamotrigine vs placebo, P=.02; lithium vs placebo, P=.006). Lamotrigine was superior to placebo at prolonging the time to a depressive episode (P=.02). Lithium was superior to placebo at prolonging the time to a manic, hypomanic, or mixed episode (P=.006). The most common adverse event reported for lamotrigine was headache. Conclusions: Both lamotrigine and lithium were superior to placebo for the prevention of relapse or recurrence of mood episodes in patients with bipolar I disorder who had recently experienced a manic or hypomanic episode. The results indicate that lamotrigine is an effective, well-tolerated maintenance treatment for bipolar disorder, particularly for prophylaxis of depression.

Original languageEnglish (US)
Pages (from-to)392-400
Number of pages9
JournalArchives of General Psychiatry
Volume60
Issue number4
DOIs
StatePublished - Apr 1 2003

Fingerprint

Bipolar Disorder
Lithium
Placebos
Therapeutics
Secondary Prevention
lamotrigine
Recurrence
Psychotropic Drugs
Controlled Clinical Trials
Headache
Depression

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. / Bowden, Charles L.; Calabrese, Joseph R.; Sachs, Gary; Yatham, Lakshmi N.; Asghar, Shaheen Akthar; Hompland, Magne; Montgomery, Paul; Earl, Nancy; Smoot, Tonya M.; DeVeaugh-Geiss, Joseph.

In: Archives of General Psychiatry, Vol. 60, No. 4, 01.04.2003, p. 392-400.

Research output: Contribution to journalArticle

Bowden, CL, Calabrese, JR, Sachs, G, Yatham, LN, Asghar, SA, Hompland, M, Montgomery, P, Earl, N, Smoot, TM & DeVeaugh-Geiss, J 2003, 'A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder', Archives of General Psychiatry, vol. 60, no. 4, pp. 392-400. https://doi.org/10.1001/archpsyc.60.4.392
Bowden, Charles L. ; Calabrese, Joseph R. ; Sachs, Gary ; Yatham, Lakshmi N. ; Asghar, Shaheen Akthar ; Hompland, Magne ; Montgomery, Paul ; Earl, Nancy ; Smoot, Tonya M. ; DeVeaugh-Geiss, Joseph. / A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. In: Archives of General Psychiatry. 2003 ; Vol. 60, No. 4. pp. 392-400.
@article{827ef0870e2d41728c10fad274e39b40,
title = "A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder",
abstract = "Background: Lamotrigine has been shown to be an effective treatment for bipolar depression and rapid cycling in placebo-controlled clinical trials. This double-blind, placebo-controlled study was conducted to assess the efficacy and tolerability of lamotrigine and lithium compared with placebo for the prevention of relapse or recurrence of mood episodes in recently manic or hypomanic patients with bipolar I disorder. Methods: After an 8- to 16-week open-label phase during which treatment with lamotrigine was initiated and other psychotropic drug regimens were discontinued, patients were randomized to lamotrigine (100-400 mg daily), lithium (0.8-1.1 mEq/L), or placebo as double-blind maintenance treatment for as long as 18 months. Results: Of 349 patients who met screening criteria and entered the open-label phase, 175 met stabilization criteria and were randomized to double-blind maintenance treatment (lamotrigine, 59 patients; lithium, 46 patients; and placebo, 70 patients). Both lamotrigine and lithium were superior to placebo at prolonging the time to intervention for any mood episode (lamotrigine vs placebo, P=.02; lithium vs placebo, P=.006). Lamotrigine was superior to placebo at prolonging the time to a depressive episode (P=.02). Lithium was superior to placebo at prolonging the time to a manic, hypomanic, or mixed episode (P=.006). The most common adverse event reported for lamotrigine was headache. Conclusions: Both lamotrigine and lithium were superior to placebo for the prevention of relapse or recurrence of mood episodes in patients with bipolar I disorder who had recently experienced a manic or hypomanic episode. The results indicate that lamotrigine is an effective, well-tolerated maintenance treatment for bipolar disorder, particularly for prophylaxis of depression.",
author = "Bowden, {Charles L.} and Calabrese, {Joseph R.} and Gary Sachs and Yatham, {Lakshmi N.} and Asghar, {Shaheen Akthar} and Magne Hompland and Paul Montgomery and Nancy Earl and Smoot, {Tonya M.} and Joseph DeVeaugh-Geiss",
year = "2003",
month = "4",
day = "1",
doi = "10.1001/archpsyc.60.4.392",
language = "English (US)",
volume = "60",
pages = "392--400",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

AU - Bowden, Charles L.

AU - Calabrese, Joseph R.

AU - Sachs, Gary

AU - Yatham, Lakshmi N.

AU - Asghar, Shaheen Akthar

AU - Hompland, Magne

AU - Montgomery, Paul

AU - Earl, Nancy

AU - Smoot, Tonya M.

AU - DeVeaugh-Geiss, Joseph

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Background: Lamotrigine has been shown to be an effective treatment for bipolar depression and rapid cycling in placebo-controlled clinical trials. This double-blind, placebo-controlled study was conducted to assess the efficacy and tolerability of lamotrigine and lithium compared with placebo for the prevention of relapse or recurrence of mood episodes in recently manic or hypomanic patients with bipolar I disorder. Methods: After an 8- to 16-week open-label phase during which treatment with lamotrigine was initiated and other psychotropic drug regimens were discontinued, patients were randomized to lamotrigine (100-400 mg daily), lithium (0.8-1.1 mEq/L), or placebo as double-blind maintenance treatment for as long as 18 months. Results: Of 349 patients who met screening criteria and entered the open-label phase, 175 met stabilization criteria and were randomized to double-blind maintenance treatment (lamotrigine, 59 patients; lithium, 46 patients; and placebo, 70 patients). Both lamotrigine and lithium were superior to placebo at prolonging the time to intervention for any mood episode (lamotrigine vs placebo, P=.02; lithium vs placebo, P=.006). Lamotrigine was superior to placebo at prolonging the time to a depressive episode (P=.02). Lithium was superior to placebo at prolonging the time to a manic, hypomanic, or mixed episode (P=.006). The most common adverse event reported for lamotrigine was headache. Conclusions: Both lamotrigine and lithium were superior to placebo for the prevention of relapse or recurrence of mood episodes in patients with bipolar I disorder who had recently experienced a manic or hypomanic episode. The results indicate that lamotrigine is an effective, well-tolerated maintenance treatment for bipolar disorder, particularly for prophylaxis of depression.

AB - Background: Lamotrigine has been shown to be an effective treatment for bipolar depression and rapid cycling in placebo-controlled clinical trials. This double-blind, placebo-controlled study was conducted to assess the efficacy and tolerability of lamotrigine and lithium compared with placebo for the prevention of relapse or recurrence of mood episodes in recently manic or hypomanic patients with bipolar I disorder. Methods: After an 8- to 16-week open-label phase during which treatment with lamotrigine was initiated and other psychotropic drug regimens were discontinued, patients were randomized to lamotrigine (100-400 mg daily), lithium (0.8-1.1 mEq/L), or placebo as double-blind maintenance treatment for as long as 18 months. Results: Of 349 patients who met screening criteria and entered the open-label phase, 175 met stabilization criteria and were randomized to double-blind maintenance treatment (lamotrigine, 59 patients; lithium, 46 patients; and placebo, 70 patients). Both lamotrigine and lithium were superior to placebo at prolonging the time to intervention for any mood episode (lamotrigine vs placebo, P=.02; lithium vs placebo, P=.006). Lamotrigine was superior to placebo at prolonging the time to a depressive episode (P=.02). Lithium was superior to placebo at prolonging the time to a manic, hypomanic, or mixed episode (P=.006). The most common adverse event reported for lamotrigine was headache. Conclusions: Both lamotrigine and lithium were superior to placebo for the prevention of relapse or recurrence of mood episodes in patients with bipolar I disorder who had recently experienced a manic or hypomanic episode. The results indicate that lamotrigine is an effective, well-tolerated maintenance treatment for bipolar disorder, particularly for prophylaxis of depression.

UR - http://www.scopus.com/inward/record.url?scp=0037385145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037385145&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.60.4.392

DO - 10.1001/archpsyc.60.4.392

M3 - Article

VL - 60

SP - 392

EP - 400

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 4

ER -